Gilead's long-awaited remdesivir price is $3,120, in line with watchdog estimates

For private insurance plans, Gilead set a list price of $520 per vial, Gilead CEO Daniel O’Day revealed Monday. The cost for a five-day treatment course using six vials, which most patients are expected to receive, would add up to $3,120. For governments of developed countries, including the U.S., the price will be lower, at $390 per vial or $2,340 per course.